Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Genomic Studies for GPCRs

By Drug Discovery Trends Editor | February 2, 2009

Genetic or genomic approaches are used to validate targets of potential therapeutic interest. Find out how genomic approaches are used in identifying GPCR targets.

Drug Discovery & Development magazine conducted a roundtable discussion with industry scientists to answer questions about GPCR. Below are the answers to a question related to genomic or genetic approaches to identify GPCR targets. To review the full discussion, see all related articles.

James Netterwald: One approach that I haven’t heard mentioned is a genetic or genomic approach to either identifying GPCR targets or validating the targets in some way. Are any of you utilizing a genomic or –omic technology in your GPCR work?

Suresh Poda: Yes, we do our initial target identification with genomic approaches. Most of the time, a lot of people have used GPCR animal knockout models to study physiology and the phenotypes. There are some recent trends in this area, knocking out the target in a particular tissue in which you are most interested. These tools are really useful at the target identification stage. It’s also important to test this hypothesis using small drug-like  molecules.

RELATED CONTENT

The GPCR Conversation Continues…
Roundtable participants offered insight on even more GPCR research trends.

  • Imaging: Live vs. Preserved Cells
  • Druggable Targets
  • Crystallized GPCRs
  • Recombinant Systems
  • Cell-based Assays
  • Meet the Participants

Charles Lunn: Genetic approaches are used to validate targets of potential therapeutic interest… If a particular receptor is of interest you genetically delete it, then test whether the resulting animal has a phenotype consistent with your model. Your results may suggest whether your therapeutic compound should be an agonist for the target receptor, or an antagonist. You can then target your screening paradigm to select compounds with the desired pharmacology. It is a widely used technique.

Richard Eglen: I think another side to that point, which may be less active than it was four or five years ago, was the deorphanization of those GPCRs … where there were many programs where orphan GPCRs—one that was from a sequence that was a novel GPCR, was characterized, and had no identified endogenous ligands—and that was advanced as a potential disease target. Clearly a lot of this was done at risk since if one didn’t know the endogenous ligand, then one wasn’t too sure whether it was involved in a disease in the first place. But my perception of this is that deorphanization in drug discovery around GPCRs tends to be less an activity than maybe it was. But certainly, genomic approaches were used to identify a whole range of novel GPCRs and how they may relate to pathophysiology.

Lunn: Part of the problem with GPCR deorphanization was that it is really hard. Such research takes a lot of time and effort from a large group of skilled investigators. Plus, successes are few—the easy receptors have already been deorphanized. It comes down to a business decision. Do you want to invest a significant part of your research dollar to seek a rare event, or rather wait until academics—who have a little more flexibility to pursue these programs—to identify a target. A decision about the therapeutic value of the target can then be determined.


Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE